Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Status:
Terminated
Trial end date:
2016-08-05
Target enrollment:
Participant gender:
Summary
This study assessed the efficacy, safety and tolerability of BAF312 administered orally in
patients with clinically active polymyositis and also in patients with polymyositis who had
shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic
drugs).